Misplaced Pages

Asandeutertinib: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactivelyContent deleted Content addedVisualWikitext
Revision as of 17:30, 30 December 2024 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,805 edits created drug stubTag: nowiki added  Latest revision as of 00:49, 2 January 2025 edit undoGraeme Bartlett (talk | contribs)Administrators249,807 edits added Category:Dimethylamino compounds using HotCat 
(3 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{Orphan|date=December 2024}}

{{cs1 config|name-list-style=vanc|display-authors=6}} {{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug {{Infobox drug
Line 18: Line 20:
| widthR = | widthR =
| altR = | altR =
| captionLR = | captionLR =


<!-- Clinical data --> <!-- Clinical data -->
Line 39: Line 41:
| ATC_prefix = | ATC_prefix =
| ATC_suffix = | ATC_suffix =
| ATC_supplemental = | ATC_supplemental =


<!-- Legal status --> <!-- Legal status -->
Line 60: Line 62:
| legal_UN = | legal_UN =
| legal_UN_comment = | legal_UN_comment =
| legal_status = | legal_status =


<!-- Pharmacokinetic data --> <!-- Pharmacokinetic data -->
Line 70: Line 72:
| elimination_half-life = | elimination_half-life =
| duration_of_action= | duration_of_action=
| excretion = | excretion =


<!-- Identifiers --> <!-- Identifiers -->
Line 108: Line 110:
| specific_rotation = | specific_rotation =
}} }}
'''Asandeutertinib''' is an ] that is being evaluated for the treatment of cancer. It is an ] (EGFR) ] (TKI) with antineoplastic properties.<ref name = "PatSnap">{{cite web | title = Asandeutertinib | url = https://synapse.patsnap.com/drug/7c59ac82af8f4fb7b9825b2a7f8f2933 | work = PatSnap }}</ref> <ref>{{cite web | title = Asandeutertinib | url = https://www.guidetomalariapharmacology.org/GRAC/LigandDisplayForward?ligandId=13201 | work = IUPHAR/BPS Guide to PHARMACOLOGY }}</ref> Developed by TYK Medicines, this small molecule drug is currently being investigated for the treatment of ] (NSCLC), particularly in patients with EGFR mutations.<ref name = "PatSnap" /><ref>{{cite journal | vauthors = Han B, Zhang W, Wu L, Chen B, Zhao Y, Liu J, He J, Liu Y, Zhang Z, Chen H, Chen X | title = P1. 12A. 07 A Phase 1 Study of TY-9591 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Positive Mutation. | journal = Journal of Thoracic Oncology | date = October 2024 | volume = 19 | issue = 10 | pages = S195 | doi = 10.1016/j.jtho.2024.09.353 }}</ref> '''Asandeutertinib''' is an ] that is being evaluated for the treatment of cancer. It is an ] (EGFR) ] (TKI) with antineoplastic properties.<ref name = "PatSnap">{{cite web | title = Asandeutertinib | url = https://synapse.patsnap.com/drug/7c59ac82af8f4fb7b9825b2a7f8f2933 | work = PatSnap }}</ref><ref>{{cite web | title = Asandeutertinib | url = https://www.guidetomalariapharmacology.org/GRAC/LigandDisplayForward?ligandId=13201 | work = IUPHAR/BPS Guide to PHARMACOLOGY }}</ref> Developed by TYK Medicines, this small molecule drug is currently being investigated for the treatment of ] (NSCLC), particularly in patients with EGFR mutations.<ref name = "PatSnap" /><ref>{{cite journal | vauthors = Han B, Zhang W, Wu L, Chen B, Zhao Y, Liu J, He J, Liu Y, Zhang Z, Chen H, Chen X | title = P1. 12A. 07 A Phase 1 Study of TY-9591 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Positive Mutation. | journal = Journal of Thoracic Oncology | date = October 2024 | volume = 19 | issue = 10 | pages = S195 | doi = 10.1016/j.jtho.2024.09.353 }}</ref>


== References == == References ==
{{reflist}} {{reflist}}

⚫ {{pharma-stub}}


] ]
] ]
] ]
]
] ]
] ]
] ]
] ]
]


⚫ {{pharma-stub}}

Latest revision as of 00:49, 2 January 2025

This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2024)

Pharmaceutical compound
Asandeutertinib
Clinical data
Other namesRunnor-9591, TY 9591
Identifiers
IUPAC name
  • N--4-methoxy-5-pyrimidin-2-yl]amino]phenyl]prop-2-enamide
CAS Number
PubChem CID
IUPHAR/BPS
UNII
Chemical and physical data
FormulaC28H30D3N7O2
Molar mass502.636 g·mol
3D model (JSmol)
SMILES
  • C()()N1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
InChI
  • InChI=InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)/i5D3
  • Key:DUYJMQONPNNFPI-VPYROQPTSA-N

Asandeutertinib is an investigational new drug that is being evaluated for the treatment of cancer. It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with antineoplastic properties. Developed by TYK Medicines, this small molecule drug is currently being investigated for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations.

References

  1. ^ "Asandeutertinib". PatSnap.
  2. "Asandeutertinib". IUPHAR/BPS Guide to PHARMACOLOGY.
  3. Han B, Zhang W, Wu L, Chen B, Zhao Y, Liu J, et al. (October 2024). "P1. 12A. 07 A Phase 1 Study of TY-9591 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Positive Mutation". Journal of Thoracic Oncology. 19 (10): S195. doi:10.1016/j.jtho.2024.09.353.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: